What is EBS's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.36B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for EBS?

P/E (TTM) is n/a and 52-week range is $4.36 to $14.06 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s EBS figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for EBS?

The company profile lists revenue (TTM) near $770M, net income (TTM) near $-17.68B, EPS (TTM) near $-3.51 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Emergent BioSolutions Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Gaithersburg, Maryland, US, 51.6M shares outstanding, ISIN US29089Q1058 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Emergent BioSolutions Inc

$EBS

Health Care · Biotechnology

IR Run Scenarios

$7.06

+3.67%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. The company is headquartered in Gaithersburg, Maryland and currently employs 900 full-time employees. The company went IPO on 2006-11-15. The company is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.

Employees

900

Website

emergentbiosolutions.com/

IPO

2006-11-15

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)